USP1 and neoplasm: KSQ-4279 (RO7623066), the first oral USP1 inhibitor to enter clinical trials, shows high selectivity and robust efficacy, including tumor regression in HR-deficient and PARPi-resistant models; combination with olaparib is synergistic (NCT05240898) [81, 85–87].